A reorganization of manufacturing sites is currently underway in the generic drug industry. With the generic drug share approaching 80% on a volume basis and NHI prices in decline, companies are looking for ways to grow and survive.In July, Nichi-Iko…
REGULATORY
LDP Going into Tax Reform Debate for FY2021
The ruling Liberal Democratic Party’s (LDP) Tax Commission held a general assembly meeting on November 19 to kick off its tax reform debate for FY2021 beginning next April. It will now begin collecting opinions from each LDP committee about their…
To read the full story
REGULATORY
- Fully Implement Off-Year Drug Re-Pricing: LDP Fiscal Consolidation HQ
November 20, 2020
- Lower House Passes Immunization Act Amendment Bill
November 20, 2020
- PAFSC Likely to Skip Review of Ono’s Cancer Cachexia Drug Yet Again
November 20, 2020
- Lilly’s Galcanezumab Up for PAFSC Review for Migraine Pretension on Dec. 2
November 19, 2020
- MHLW Mulls Health Follow-Up on 10,000-Plus COVID-19 Vaccine Recipients
November 19, 2020
Measures focusing on risk management should be necessary to prevent disruptions in API supplies, Prof. Hiroyuki Sakamaki of Kanagawa University…
Nearly a year after the introduction of the Ministry of Health, Labor and Welfare’s (MHLW) drug promotion guidelines in April…
Advancements in modified oligonucleotide technologies has been the key driver behind a spate of approvals in the oligonucleotide therapeutics space…
Japan’s key reimbursement policy panel on December 20 approved an outline of its FY2020 drug pricing reform next April, with…
The Ministry of Health, Labor and Welfare (MHLW) on November 27 added to the NHI price list Japan’s first biosimilars of Avastin (bevacizumab), Nesp (darbepoetin alfa), and Forteo (teriparatide). The NHI prices of first biosimilars are set at 70% of…
A total of 51 new drugs joined the NHI price list in 2019, which are expected to generate combined peak sales of 373 billion yen, according to Jiho’s tally of data submitted to a key reimbursement policy panel. The relatively…
Some seven years in the making, Japan’s Ministry of Health, Labor and Welfare (MHLW) finally rolled out a cost-effectiveness assessment…
Japan will go ahead with the introduction of a cost-effectiveness assessment (CEA) scheme for drugs and medical devices in April…
As I skied the slopes of Hakuba in January, I never would have imagined the world would be in a complete lockdown just a few months later. There’s no question this has been an incredibly challenging year, but there’s good…